...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Young Pharmacists >The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain
【24h】

The Effect of Pregabalin on the Quality of Life in Patients with Central Post-Stroke Pain

机译：普瑞巴林对中风后中风患者生活质量的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Pregabalin is an off-label drug used to reduce central neuropathy pain that often accompanies and affects the quality of life in central poststroke pain (CPSP). This study was conducted to determine the effect of pregabalin on CPSP. Methods: Patients with CPSP who were prescribed pregabalin 75 mg/day for treatment were included in this study. The severity of pain (worst, least, average, and right now) and the quality of life were assessed with a Brief Pain Inventory (short form) (BPI-sf) questionnaire. The assessment was conducted before treatment, in week 4, and at the end of treatment (week 12). The Friedman test and, subsequently, the Wilcoxon post-hoc test was conducted to compare the severity of pain and the quality of life before and after therapy. Results: A total of 36 patients with CPSP (21 male and 15 female) were included. The study found a reduction in the severity of pain after four weeks of treatment and after 12 weeks of treatment (CI 95%, p <0.05). A minor change of the quality of life significantly improved in week 4 in all sub-items of the BPI-sf questionnaire (general activity, mood, walking ability, work, relations with others, sleep, enjoyment of life) (CI 95%, p <0.05). After 12 weeks of treatment, the quality of life demonstrated a mild change in all sub-items. The major adverse event shown in this study was somnolence (13.89%). Conclusion: Pregabalin is safe and effective in reducing the severity of pain as well as improving the quality of life in Indonesian patients with CPSP.
机译：目的：普瑞巴林是一种减标签药物，用于减轻中枢性中风后疼痛（CPSP）经常伴随并影响生活质量的中枢神经病性疼痛。进行这项研究以确定普瑞巴林对CPSP的作用。方法：本研究包括CPSP患者，他们接受普瑞巴林75 mg /天的治疗处方。使用简短疼痛量表（简称BPI-sf）问卷评估疼痛的严重程度（最差，最差，平均和现在）和生活质量。评估是在治疗前，治疗第4周和治疗结束时（第12周）进行的。进行了Friedman检验和随后的Wilcoxon事后检验，以比较治疗前后疼痛的严重程度和生活质量。结果：共纳入36例CPSP患者（男性21例，女性15例）。研究发现，在治疗4周和治疗12周后，疼痛的严重程度有所减轻（CI 95％，p <0.05）。在BPI-sf问卷的所有子项目（一般活动，情绪，步行能力，工作，与他人的关系，睡眠，生活享受）中，生活质量的微小变化在第4周都得到了显着改善（CI为95％， p ＜0.05）。经过12周的治疗，生活质量在所有子项目中均显示出轻微的变化。这项研究显示的主要不良事件是嗜睡（13.89％）。结论：普瑞巴林可安全有效地减轻印度尼西亚CPSP患者的疼痛程度并改善其生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号